GENESIS Pharma Secures Exclusive Rights to Donidalorsen for Hereditary Angioedema in CEE
- January 2, 2026
Renalys Pharma Announces Positive Phase III Results for Sparsentan in Japanese IgA Nephropathy Patients
Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial
FDA Approves Enhertu Combination for First-Line HER2-Positive Breast Cancer
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
GENESIS Pharma has earned exclusive rights from Otsuka Pharmaceutical to distribute their HAE drug donidalorsen across multiple European countries. Read more here:
patientworthy.com/2026/01/02/genesis-pharma-secures-exclusive-rights-to-donidalorsen-for-heredita...
Many people don’t know about congenital adrenal hyperplasia (CAH). Raising awareness helps patients get the recognition, understanding, and support they deserve every day! #CAH #RareDiseaseOfTheWeek #RareDiseaseAwareness #ShareYourStory #PatientWorthy
Renalys Pharma has announced strong results in a recent Phase III study in Japan, showing positive effects on IgAN patients treated with sparsentan. Read more here:
patientworthy.com/2026/01/01/renalys-pharma-announces-positive-phase-iii-results-for-sparsentan-i...
